Using a comparator group, researchers sought to determine the impact of a diagnosis of solid tumor on outcomes among postsurgical ICU admissions in patients with cancer vs those without cancer.
Tazemetostat demonstrated preclinical activity against EZH2-mutant non-Hodgkin lymphomas.
[Breast Cancer: Targets and Therapy] A review of studies investigating the efficacy of buparlisib monotherapy and in combination with various other anticancer agents in the treatment of breast cancer and other solid tumors.
Study results demonstrate that statins have antitumor activity in various solid-tumor cancers and leukemia; however, experts offer these caveats on using them to treat cancer — at least for now.
The US FDA has granted expanded clearance for the DigniCap Cooling System to include use in patients undergoing chemotherapy for solid tumors in other areas of the body besides the breast.
Combining extracorporeal shock wave (ESW) technique with nanoparticle delivery improves treatment of difficult-to-treat solid tumors, such as anaplastic thyroid cancer.
Oncolytic variants of the HSV-1 have successfully treated melanoma, glioma, and other cancers in adults; in this study, researchers test the effectiveness of an oncolytic HSV-1 in pediatric patients.
A potential treatment targeting neutrophils holds promise for limiting kidney damage and improving renal function in cancer.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
Researchers from 3 Texas institutions collaborated on a multiscale framework for modeling tumor growth, with potential to inform growth patterns and tumor density.
Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian CancerApril 20, 2017
Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.
The combination of an anticancer agent with a rheumatoid arthritis medication results in synergistic effect that improves the efficacy of the anticancer agent.
The mechanism of metronomic chemotherapy: Improved tumor blood supply leads to better treatment .
Researchers develop novel strategy for delivering immunotherapy agents to tumor surgical sites to eradicate tumor cells left behind after resection and reduce risk of recurrence.
With only 1 slide of a tumor section, an analysis of multiple tumor markers can be performed. The technique may help predict response to immunotherapy, which typically evokes responses in only a small group of patients.
Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.
A single dose and a beam of light can kill up to 95% of cancer cells in 2 hours, according to preclinical research on a novel approach to tumor resection. Photodynamic cancer therapy may be a treatment option for people whose tumors are inoperable or hard-to-reach.
A widely prescribed pain/anti-inflammatory medication reduced the growth of neurofibromatosis type 2 tumors in mice and in cell cultures, suggesting that the drug could reduce tumor growth in some cancers.
Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.
Gene therapy with a T cell receptor targeting a single cancer-specific point mutation is being used to eradicate large solid tumors.
Potential Drug Targets Are Identified With Finding That Genes in the Ly6 Gene Family Drive Tumorigenesis and Poor PrognosisFebruary 25, 2016
Lower patient survival and worse clinical outcomes across a variety of cancer types were correlated with increased expression of 4 genes in the Ly6 gene family. These findings came from an analysis of 130 gene expression studies from 10 solid cancers.
Analyzing tumor DNA fragments in the bloodstream, known as circulating tumor DNA (ctDNA), may offer a more complete view of a patient's cancer from a molecular perspective.
Optical probes that make cancer cells glow and improve surgical tumor removal are in phase I and II clinical trials in humans. The probes could be commonplace in the next 5 to 10 years, hypothesize the researchers.
A new injectable agent causes cancer cells in a tumor to fluoresce, potentially enabling surgeons to locate and remove all of a cancerous tumor on the first attempt.
Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.
Genetic analyses and other tests performed by both researchers and physicians can be significantly skewed when normal cells, especially immune cells, are intermixed with cancerous cells in a tissue sample.
A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.
The size of a surgically removed tumor is generally thought to relate to the risk of metastasis; however, tumor cells metastasize at different times therefore the rate of spread is difficult to assess. A mathematical model was developed to calculate the relationship between tumor size and the relative risk of recurrence after surgery.
An FDA-approved, magnetic nanoparticle and MRI identifies tumors most likely to respond to drugs delivered via nanoparticles.
A new study has found an additional mechanism explaining how EGFR, a molecule long linked to cancer progression appears, to seed the body with metastatic cells long before doctors would typically detect a primary tumor.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|